Gujarat Kidney And Super Speciality Limited (GKSL)
₹187.37 -1.20% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Gujarat Kidney's revenue was ₹34.3 Cr, and net profit ₹5.3 Cr; the operating margin was 24.4%.
| Q1 FY27 (₹ Cr) | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹34.3 | — | — |
| Operating profit | ₹8.4 | — | — |
| Net profit | ₹5.3 | — | — |
| EPS (₹) | 0.66 | — | — |
| Operating margin | 24.4% | — | — |
GKSL delivery percentage and bulk deals
NSE end-of-day data for
On Fri, 16 Oct 2026, 34.32% of the GKSL shares traded on NSE were taken to delivery, against the stock's own 20-session average of 36.96%. That is close to its usual level. Volume was 0.2 times its average, well below normal. 36 bulk or block deals were reported in GKSL in the last 60 days: ₹242 Cr bought and ₹250 Cr sold.
Delivery in the last 5 sessions: 32.1% · 35.4% · 35.3% · 49.6% · 34.3%
| Date | Side | Counterparty | Value | Price | Quantity | Type |
|---|---|---|---|---|---|---|
| 7 Oct | Sell | Natvarsinh T Chavda | ₹9.34 Cr | ₹192.19 | 486,148 | Bulk |
| 7 Oct | Buy | Natvarsinh T Chavda | ₹8.90 Cr | ₹188.97 | 471,148 | Bulk |
| 5 Oct | Sell | Natvarsinh T Chavda | ₹13.86 Cr | ₹192.11 | 721,367 | Bulk |
| 5 Oct | Buy | Natvarsinh T Chavda | ₹13.64 Cr | ₹189.10 | 721,367 | Bulk |
| 5 Oct | Buy | Qe Securities Llp | ₹8.54 Cr | ₹192.61 | 443,342 | Bulk |
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Gujarat Kidney And Super Speciality Limited disclosed the voting results and scrutinizer report for its 7th Annual General Meeting held on September 28, 2026. All 12 resolutions were approved with requisite majority, with overall voter participation at 72.36% (5,70,48,269 votes polled out of 7,88,43,250 outstanding shares). Key approvals included adoption of FY 2025-26 financials, director appointments, raising limits for loans/investments under Section 186, and approval of related-party transactions.
- All 12 resolutions approved with requisite majority at the 7th AGM held on September 28, 2026
- 72.36% total votes polled (57,048,269 out of 78,843,250 shares), dominated by promoter participation (56,333,900 shares)
- Approved raising the threshold of loans/guarantees/securities under Section 186 and loans under Section 185
- Passed ordinary resolution for related party transactions
Gujarat Kidney And Super Speciality Limited has issued the notice for its 7th Annual General Meeting scheduled for September 28, 2026. Key special resolutions include doubling the annual remuneration of Managing Director Pragnesh Bharpoda from Rs 18 lakh to Rs 36 lakh effective October 1, 2026. Additionally, the company seeks shareholder approval for appointing two Independent Directors for 5-year terms and clearing various related party transactions, including professional fees up to Rs 50 lakh each for certain directors and relatives.
- 7th Annual General Meeting scheduled to be held in physical mode on September 28, 2026
- Proposed increase in MD Pragnesh Bharpoda's remuneration from Rs 18 lakh to Rs 36 lakh per annum
- Appointment of SPANJ & Associates as Secretarial Auditors for a 5-year term (FY2026-27 to FY2030-31)
- Approval sought for related party professional fees up to Rs 50 lakh each to key personnel and relatives
Gujarat Kidney And Super Speciality Limited has published pre-advertisement newspaper notices regarding its upcoming 7th Annual General Meeting (AGM). The AGM is scheduled to take place on Monday, September 28, 2026, at 09:30 AM IST in physical mode. The statutory notices were published on September 1, 2026, in Financial Express (Ahmedabad edition) and Gujarat Mitra (Gujarati edition). This is a routine regulatory intimation pursuant to SEBI Listing Regulations.
- 7th Annual General Meeting to be held on Monday, September 28, 2026, at 09:30 IST
- AGM to be conducted in physical mode pursuant to MCA circulars
- Pre-advertisement published on September 1, 2026, in Financial Express and Gujarat Mitra
- Filing submitted under Regulations 30 and 47 of SEBI LODR Regulations
Gujarat Kidney And Super Speciality Limited (GKSL) has informed the exchanges that its management will participate in the GIA Healthcare Day on August 31, 2026. The event is a physical group meeting scheduled from 10:00 AM to 11:00 AM IST at Jio World Convention Centre, BKC, Mumbai. The company noted that the interaction will rely solely on publicly available information with no unpublished price sensitive information (UPSI) discussed. The meeting was arranged on shorter notice following the recent onboarding of Go India Advisors as its IR and PR agency.
- Management participating in GIA Healthcare Day on August 31, 2026
- Meeting format is a physical group session scheduled between 10:00 AM and 11:00 AM IST
- Location fixed at Jio World Convention Centre, Bandra-Kurla Complex (BKC), Mumbai
- Company confirmed discussions will strictly use publicly available information
Gujarat Kidney And Super Speciality Limited announced the appointment of Dr. Disha Bharpoda as an Additional Non-Executive Independent Director for a 5-year term effective August 24, 2026, subject to shareholder approval. The appointee holds an MD in Radiology with 5 years of senior resident experience. Additionally, the Board took note of shareholder approval via postal ballot for a special resolution regarding variation in the objects and utilization terms of its IPO proceeds.
- Appointed Dr. Disha Bharpoda as Additional Non-Executive Independent Director effective August 24, 2026.
- Appointment is for a first term of 5 consecutive years, subject to approval at the next AGM.
- Board noted shareholder approval via Postal Ballot for variation in the objects/terms of IPO proceeds utilization.
- Board meeting commenced at 4:30 PM and concluded at 5:00 PM on August 24, 2026.
Gujarat Kidney And Super Speciality Limited (GKSL) has appointed Dr. Disha Bharpoda as an Additional Non-Executive Independent Director for a 5-year term starting August 24, 2026, subject to shareholder approval at the upcoming AGM. Dr. Bharpoda holds an MD in Radiology (2021) and has 5 years of senior resident medical experience. Additionally, the Board took note of shareholder approval via postal ballot for a special resolution regarding variation in the objects and terms of utilization of its IPO proceeds. The filing notes no familial relationship between the newly appointed director and existing board members.
- Dr. Disha Bharpoda appointed as Additional Non-Executive Independent Director effective August 24, 2026
- Term of appointment is fixed for 5 consecutive years, subject to AGM shareholder confirmation
- Board recorded shareholder approval via postal ballot for a special resolution to vary IPO proceeds utilization
- Dr. Bharpoda completed MD in Radiology in 2021 with 5 years of residency experience
Gujarat Kidney And Super Speciality Limited appointed Dr. Disha Bharpoda as an Additional Non-Executive Independent Director for a 5-year term, effective August 24, 2026. The appointment is subject to approval by shareholders at the upcoming Annual General Meeting. Additionally, the Board noted shareholder approval via Postal Ballot regarding variation in the objects/terms of IPO proceeds utilization.
- Appointment of Dr. Disha Bharpoda as Additional Non-Executive Independent Director effective August 24, 2026
- Appointed for a first term of 5 consecutive years, subject to shareholder approval
- Shareholder approval received via Postal Ballot for variation in IPO proceeds utilization terms
- Director holds an MD in Radiology (2021) with 5 years as Senior Resident Doctor
Gujarat Kidney And Super Speciality Limited submitted the statutory auditor's limited review reports for its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. Statutory auditor Y. M. Shah & Co. issued an unmodified clean review report with no material misstatements or qualifications highlighted. The filing fulfills regulatory requirements under Regulation 33 of the SEBI LODR Regulations. Detailed financial tables were omitted from the provided report extract.
- Submitted unaudited standalone and consolidated financial review reports for the quarter ended June 30, 2026.
- Statutory auditor Y. M. Shah & Co. issued clean review reports dated August 14, 2026.
- Review performed in accordance with SRE 2410 standards with zero auditor qualifications.
- Promoter holding stood at 71.45% as of June 2026.
Gujarat Kidney And Super Speciality Limited has submitted its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026. The independent statutory auditor, Y. M. Shah & Co., has issued an unmodified limited review report confirming compliance with Ind AS 34. The detailed P&L table was not included in the review report extract, but the submission satisfies quarterly regulatory compliance under Regulation 33. Investors should review the complete financial table once fully accessible on the exchange.
- Board approved unaudited standalone and consolidated financial results for Q1 ended June 30, 2026.
- Statutory auditor Y. M. Shah & Co. issued a clean limited review report with no qualifications on August 14, 2026.
- Compliance fulfilled under Regulation 33 of SEBI Listing Obligations and Disclosure Requirements.
- Promoter shareholding stood stable at 71.45% as of the June 2026 quarter.
Gujarat Kidney And Super Speciality Limited has appointed Mr. Paresh Dhoti as an Additional Non-Executive Independent Director for a 5-year term effective August 14, 2026. Mr. Dhoti, who was initially inducted as a Non-Executive Non-Independent Director on July 9, 2026, has now been reclassified to Independent status. He holds a Bachelor of Dentistry degree (2006) and has been practicing independently in Vadodara for 18 years. The appointment is subject to member approval at the upcoming Annual General Meeting.
- Appointed Mr. Paresh Dhoti as Additional Non-Executive Independent Director effective August 14, 2026
- First term approved for 5 consecutive years, not liable to retire by rotation (subject to shareholder approval)
- Reclassified from his previous Non-Executive Non-Independent role approved on July 9, 2026
- Appointee has 18 years of professional dental practice experience in Vadodara (BDS, 2006)
Gujarat Kidney And Super Speciality Limited submitted its Regulation 32 Statement of Deviation/Variation for the quarter ended June 30, 2026. The company had raised ₹250.80 crore via an Initial Public Offering on December 24, 2025. It noted a variation in the use of proceeds that was previously approved by shareholders via a Postal Ballot special resolution on April 25, 2026. Both the Audit Committee and statutory auditors reviewed the report with no adverse comments.
- Total funds raised via IPO on 24.12.2025 stood at ₹250.80 Cr
- Reported variation in proceeds utilisation was previously approved by shareholders on 25.04.2026
- Monitoring agency Brickwork Ratings India Private Limited oversees fund utilisation
- Audit Committee and Auditors reported no adverse comments for the quarter ended June 30, 2026
Gujarat Kidney And Super Speciality Limited (GKSL) has responded to NSE queries regarding its financial results for the quarter ended September 30, 2025. The company confirmed it paid a penalty in April 2026 for the delayed submission of results originally filed on March 25, 2026. Additionally, it has resubmitted corrected XBRL filings to address data entry errors in the Consolidated Cash Flow Statement and half-yearly figures. These administrative corrections do not alter the underlying financial performance previously reported.
- Financial results for the quarter ended 30-Sep-2025 were submitted on 25-March-2026
- Penalty for delayed submission was paid by the company in April 2026
- Corrected mismatch in Consolidated Cash Flow Statement figures between XBRL and PDF formats
- Resubmitted XBRL utility on 04-August-2026 following NSE clarification request dated 31-July-2026
Gujarat Kidney And Super Speciality Limited (GKSL) has issued a clarification regarding the appointment of Mr. Paresh Dhoti, effective July 9, 2026. Originally intended as a Non-Executive Independent Director, his status has been changed to Non-Executive Non-Independent due to technical issues in completing his registration with the IICA database. The company intends to re-appoint him as an Independent Director in the next board meeting. Mr. Dhoti brings 18 years of medical practice experience in Vadodara to the board.
- Appointment of Mr. Paresh Dhoti effective from July 9, 2026
- Mr. Dhoti has 18 years of independent dental practice experience in Vadodara
- Status changed from Independent to Non-Independent due to IICA registration technicalities
- Company reported Dec 2025 quarterly revenue of ₹12.93 cr
- Re-appointment as Independent Director planned for the next board meeting
Gujarat Kidney And Super Speciality Limited (GKSL) has responded to a clarification sought by the National Stock Exchange regarding its financial results for the quarter ended March 31, 2026. The company identified a typographical error in the signing date of its Standalone Financial Statements submitted on May 28, 2026. GKSL confirmed that this clerical error has no impact on the reported financial figures, disclosures, or the substance of the results. The company is in the process of uploading the corrected documents to its website.
- Clarification issued regarding financial results originally submitted on 28-May-2026
- Error identified as a purely typographical/clerical mistake in the signing date of the statements
- Company confirms the error has zero impact on financial figures or disclosures
- Corrected Standalone Financial Statements to be published on the company website
- Internal checks to be enhanced to avoid recurrence of such clerical errors
Gujarat Kidney And Super Speciality Limited (GKSL) has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by its Registrar and Share Transfer Agent (RTA), MUFG Intime India Pvt Ltd, confirms the processing of share dematerialization requests for the period ending June 30, 2026. This is a standard administrative filing required for all listed entities to ensure that share records are accurately maintained with depositories. There is no impact on the company's financial performance or business operations.
- Compliance certificate submitted for the quarter ended June 30, 2026
- Certificate issued by Registrar and Share Transfer Agent MUFG Intime India Pvt Ltd
- Filing submitted to BSE and NSE on July 10, 2026
- Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Growth Strategy
The company aims to achieve growth through its positioning as a super-speciality hospital, specifically focusing on kidney care. The strategy involves maintaining NABH accreditation standards to attract patients and potentially expanding service offerings within its Vadodara facility to increase patient throughput and revenue per bed.
Products & Services
Super-speciality healthcare services, nephrology treatments, kidney-related surgeries, and general hospital care services.
Brand Portfolio
Gujarat Kidney and Super Speciality Hospital
Strategic Alliances
The company maintains a relationship with MUFG Intime India Private Limited (formerly Link Intime India Private Limited) for share registry and transfer services.
External Factors
Industry Trends
The healthcare industry is trending toward specialized care and accreditation-driven quality. GKSL is positioned as an NABH-accredited hospital, which is critical for empanelment with insurance providers and corporate clients, potentially increasing patient volume as the demand for organized healthcare grows in Gujarat.
Competitive Moat
The company's moat is built on its specialized focus on kidney care and its NABH accreditation. This provides a competitive advantage in the Vadodara region by establishing trust and quality benchmarks that are difficult for smaller, unorganized clinics to replicate, ensuring a steady flow of specialized cases.
Regulatory & Governance
Industry Regulations
Operations are governed by healthcare-specific regulations including the Clinical Establishments Act and Bio-Medical Waste Management Rules. Compliance with NABH (National Accreditation Board for Hospitals & Healthcare Providers) standards is maintained to ensure operational quality and safety.
Risk Analysis
Geographic Concentration Risk
The company has 100% geographic concentration in Vadodara, Gujarat. This makes the business highly vulnerable to local economic shifts, regional competition, and state-specific healthcare policy changes which could impact patient footfall and revenue.
